Assured Guaranty (AGO) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants Robert Tucker - Senior Managing Director of Investor Relations & Corporate CommunicationsDominic Frederico - President & CEORobert Bailenson - Chief Operating OfficerBenjamin Rosenblum - Chief Financial OfficerTommy McJoynt - Director - Equity Research Conference Call Participants Marissa Lobo - Analyst Operator Good morning, and welcome to the Assured Guaranty Limited First Quarter twenty twenty five Earnings Confere ...

Victory Capital (VCTR) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants Matthew Dennis - Chief of Staff & Director of Investor RelationsDavid Brown - Chairman of the Board of Directors & CEOMichael Policarpo - President, CFO & Chief Administrative OfficerAlexander Blostein - Managing DirectorRandy Binner - Managing DirectorMichael Cyprys - Managing DirectorKenneth Lee - Vice President Conference Call Participants Michael Cho - AnalystNone - Analyst Operator Good morning, and welcome to th ...

TeraWulf (WULF) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 Greetings and welcome to the TerraWolf twenty twenty five First Quarter Earnings Conference Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, John Larkin, Senior Vice President, Director of Investor Relations. Thank you, sir. You may begin. Speaker1 Thank y ...

ANI Pharmaceuticals (ANIP) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 everyone, and welcome to today's ANI Pharmaceuticals Inc. First Quarter twenty twenty five Earnings Results Call. Please note this call is being recorded. After the speakers' opening remarks, there will be a question and answer session. It is now my pleasure to turn the conference over to Lisa Wilson. Speaker1 Thank you, operator. Welcome to ANI Pharmaceuticals Q1 twenty twenty five earnings results call. This is Lisa Wilson, ...

Financial Data and Key Metrics Changes - The company reported a 38% year-over-year revenue growth in the first quarter of 2025, achieving $280 million in directional revenue guidance for the year [6][20] - Cash flow from operations reached a record $19.7 million [6] - The company aims to generate approximately $232 million in revenue over the remaining three quarters of the year [6] Business Line Data and Key Metrics Changes - Vevi revenue increased by 35% sequentially from $16 million in Q4 2024 to $21.5 million in Q1 2025, prior to the launch of the VIVI Access for All program [7][12] - iHizo's sales were impacted by destocking in Q1 2025, but unit sales more than doubled in April compared to the monthly average in Q1 [15][16] - Triassence completed critical market access initiatives in Q1, leading to a doubling of accounts ordering the product since the beginning of the year [18][19] Market Data and Key Metrics Changes - The company noted seasonality in its business, with Q1 typically being the weakest revenue period [9] - The specially branded products faced challenges due to volatility in gross to net estimates, affecting recognizable revenue [10] Company Strategy and Development Direction - The company is focused on achieving and potentially exceeding its 2025 revenue guidance through various product lines, including Vevi, iHizo, and Triassence [6][20] - The VeeVai Access for All program is expected to significantly impact revenue growth, with the potential to become a leading product in the dry eye medication market [12][14] - The company is not planning to exit the compounding business, emphasizing its importance in building commercial relationships and credibility [32][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting revenue guidance, citing strong momentum in new prescriptions and refill rates for Vevi [11][21] - The company anticipates that the third quarter will see stronger numbers driven by compounding effects from new prescriptions [23] - Management acknowledged the need for improvement in certain product lines and plans to review current strategies [59] Other Important Information - The company expects to deliver over $50 million in revenue from iHizo in 2025, with significant growth anticipated [22] - The ImprimisRx compounding business is projected to deliver more than $80 million in revenue in 2025 [22] Q&A Session Summary Question: Price increase initiatives for iHizo - Management indicated that there were no significant price increases for iHizo, and some price decreases were implemented to enhance accessibility [26][29] Question: Project Beagle initiatives - Management clarified that Project Beagle focuses on transitioning Clarity C patients to Vevi, which is expected to be financially beneficial [30][32] Question: Sequential changes in iHizo - Management noted that unit demand is returning to growth mode, with expectations for incremental growth in Q2 [38][41] Question: Triassence volume inflection - Management reported that many new accounts are beginning to use Triassence, with positive signs of adoption in various care settings [44][46] Question: Impact of tariffs on products - Management estimated a negligible impact of current tariff policies on gross margins, around 50 basis points [68][70] Question: Debt refinancing plans - Management expressed confidence in successfully restructuring debt by late summer or early fall, with positive discussions ongoing with lenders [85][86]

Brighthouse Financial (BHF) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to Brighthouse Financial's First Quarter twenty twenty five Earnings Conference Call. My name is Michelle, and I will be your coordinator today. At this time, all participants are in a listen only mode. We will facilitate a question and answer session towards the end of the conference call. In fairness to all participants, please limit yourself to one question and one follow-up ...

Embecta (EMBC) Q2 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 And long term success. Turning to some fiscal second quarter highlights. Second quarter revenue totaled $259,000,000 which exceeded our expectations of between $250,000,000 and $255,000,000 that we provided on our last earnings call. As compared to the midpoint of our prior guidance range, approximately half of the overachievement in the quarter was due to constant currency performance, while the other half was due to foreign exchange be ...

Victory Capital (VCTR) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 Good morning, and welcome to the Victory Capital First Quarter twenty twenty five Earnings Conference Call. All callers are on a listen only mode. Following the company's prepared remarks, there will be a question and answer session. I will now turn the call over to Mr. Matthew Dennis, Chief of Staff and Director of Investor Relations. Please go ahead, Mr. Dennis. Speaker1 Thank you. Before I turn the call over to David Brown, I ...

Financial Data and Key Metrics Changes - The company reported a consolidated GAAP net loss of $62 million or a negative $1.28 per share for Q1 2025, compared to a net loss of $86 million or a negative $1.84 per share for Q1 2024, indicating an improvement in financial performance [9][10] - The adjusted net loss for Q1 2025 was $8 million or a negative $0.16 per share, compared to an adjusted net loss of $24 million or a negative $0.52 per share for Q1 2024, reflecting a favorable change primarily due to lower losses in LAE [12][13] - The book value per share decreased by $1.23 to a negative $42.22 as of March 31, 2025, from a negative $40.99 as of December 31, 2024, primarily due to the consolidated net loss [13] Business Line Data and Key Metrics Changes - National reported statutory net income of $4 million for Q1 2025, compared to a statutory net loss of $11 million for Q1 2024, driven by lower losses in LAE related to PREPA exposure [15][16] - MBIA Insurance Corp reported statutory net income of $2 million for Q1 2025, compared to a statutory net loss of $35 million for Q1 2024, also due to lower losses in LAE [16][17] - The gross par amount outstanding for National's insured portfolio declined by approximately $500 million from year-end 2024 to about $25 billion as of March 31, 2025 [7] Market Data and Key Metrics Changes - National's leverage ratio of gross par to statutory capital was 27 to 1 at the end of Q1 2025, with total claims paying resources of $1.5 billion and statutory capital surplus exceeding $900 million [8] Company Strategy and Development Direction - The company continues to prioritize resolving National's PREPA exposure, which remains uncertain, and believes that reducing uncertainty regarding PREPA is essential for maximizing shareholder value [7] - The management expressed optimism about the potential resolution of the PREPA situation, indicating that the focus is shifting towards addressing key litigation issues [24] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the complexity of the PREPA situation and emphasized ongoing discussions in Washington, D.C., while expressing cautious optimism about moving into a different phase regarding the resolution [22][24] - The overall portfolio performance is consistent with expectations, with no significant concerns regarding other credits [25] Other Important Information - The corporate segment had total assets of approximately $685 million as of March 31, 2025, including unencumbered cash and liquid assets totaling $378 million [14] Q&A Session Summary Question: What is being done politically to resolve the PREPA situation? - Management highlighted that fixing PREPA is a top priority for Governor Gonzalez and that there are ongoing conversations in D.C. to facilitate resolution, with optimism about moving into a different phase [22][24] Question: Are there concerns about further write-offs in the National portfolio? - Management confirmed that the portfolio is performing within expectations and that PREPA is the primary focus, with no significant concerns about other credits [25]

Assured Guaranty (AGO) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 Good morning, and welcome to the Assured Guaranty Limited First Quarter twenty twenty five Earnings Conference Call. My name is Ezra, and I will be the operator for today's call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. I would now like to turn the conference over to our host, Robert Tucker, Senior Managi ...